Artcline

Focus: Artcline is a German biotech company specializing in functional sepsis therapy, with a focused pipeline addressing a critical unmet need in infectious diseases. The company operates as a public-stage biotech with a narrow therapeutic focus on septic shock treatment.

Infectious Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Artcline

AI assessmentNot Hiring

No open roles listed right now. Follow Artcline to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy - Observati

Severe Sepsis

N/A

Clinical Trials (1)

NCT06143137Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy - Observational Long-term Outcome Follow up

N/A

Help build intelligence for Artcline

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on ARTICE in Phase 2 for septic shock, a high-mortality acute care indication with significant clinical need
Rostock location offers potential cost-of-living advantage and access to European biotech talent networks
Public company status suggests regulatory transparency and potential for equity upside tied to pipeline progression

Watch Out For

Only 1 active job opening signals very limited hiring and constrained career mobility within the organization
Absence of revenue, financials, and cash position data raises questions about financial runway and commercial viability

Generated by Claude from Artcline's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ARTICE

Septic Shock

Phase 2

Clinical Trials (2)

NCT05442710Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy

Phase 2

NCT07388628ARTICE® Real Data Collection & Observational Trial, Phase 4 Study

N/A